23rd Aug 2018 15:44
LONDON (Alliance News) - Polarean Imaging PLC said Thursday it has enrolled the first patient in its phase III clinical trial for 129-Xenon MRI.
The study aim to prove the non-inferiority of the company's drug-device combination, using hyperpolarised 129-Xenon gas MRI, against an approved comparator, 133-Xenon scintigraphy.
The company will enrol 80 patients in total in the study from two patient populations.
On Wednesday, Polarean reported a wider interim loss, mainly due to costs related to its float in London in March.
Later on Thursday, Amphion Innovations PLC, owner of a 21.7% stake in Polarean, noted the announcement.
Polarean shares were trading up 1.3% at 15.20 pence while Amphion shares were untraded at 0.72p.
Related Shares:
AMP.Lpolarean